Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:296710.
doi: 10.1155/2012/296710. Epub 2012 Mar 18.

Efficacy and Safety of Duloxetine in Patients with Chronic Low Back Pain Who Used versus Did Not Use Concomitant Nonsteroidal Anti-Inflammatory Drugs or Acetaminophen: A Post Hoc Pooled Analysis of 2 Randomized, Placebo-Controlled Trials

Vladimir Skljarevski  1 , Peng Liu, Shuyu Zhang, Jonna Ahl, James M Martinez
Affiliations

Efficacy and Safety of Duloxetine in Patients with Chronic Low Back Pain Who Used versus Did Not Use Concomitant Nonsteroidal Anti-Inflammatory Drugs or Acetaminophen: A Post Hoc Pooled Analysis of 2 Randomized, Placebo-Controlled Trials

Vladimir Skljarevski et al. Pain Res Treat. 2012.

Abstract

This subgroup analysis assessed the efficacy of duloxetine in patients with chronic low back pain (CLBP) who did or did not use concomitant nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen (APAP). Data were pooled from two 13-week randomized trials in patients with CLBP who were stratified according to NSAID/APAP use at baseline: duloxetine NSAID/APAP user (n = 137), placebo NSAID/APAP user (n = 82), duloxetine NSAID/APAP nonuser (n = 206), and placebo NSAID/APAP nonuser (n = 156). NSAID/APAP users were those patients who took NSAID/APAP for at least 14 days per month during 3 months prior to study entry. An analysis of covariance model that included therapy, study, baseline NSAID/APAP use (yes/no), and therapy-by-NSAID/APAP subgroup interaction was used to assess the efficacy. The treatment-by-NSAID/APAP use interaction was not statistically significant (P = 0.31) suggesting no substantial evidence of differential efficacy for duloxetine over placebo on pain reduction or improvement in physical function between concomitant NSAID/APAP users and non-users.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Estimated least-squares (LS) mean changes from baseline and standard errors in BPI average pain severity in patients who concomitantly used or did not use NSAID or APAP.
Figure 2
Figure 2
Estimated least-squares (LS) mean changes from baseline and standard errors in RMDQ rating in patients who concomitantly used or did not use NSAID or APAP.
Figure 3
Figure 3
Percentage of patients who felt “much better” or “very much better” at endpoint.
See this image and copyright information in PMC

References

    1. Andersson GBJ. Epidemiological features of chronic low-back pain. The Lancet. 1999;354(9178):581–585. - PubMed
    1. Manchikanti L. Epidemiology of low back pain. Pain Physician. 2000;3(2):167–192. - PubMed
    1. Chang V, Gonzalez P, Akuthota V. Evidence-informed management of chronic low back pain with adjunctive analgesics. Spine Journal. 2008;8(1):21–27. - PubMed
    1. Chou R, Huffman LH. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Annals of Internal Medicine. 2007;147(7):505–514. - PubMed
    1. Kuijpers T, Van Middelkoop M, Rubinstein SM, et al. A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain. European Spine Journal. 2011;20(1):40–50. - PMC - PubMed

LinkOut - more resources